



**DATE:** JANUARY 26, 2021

**SUBJECT:** EIDOS THERAPEUTICS, INC. (ELECTION MERGER) – CONTRACT  
ADJUSTMENT  
OPTION SYMBOLS: 1/26/21 – EIDX remains EIDX  
1/27/21 – EIDX becomes BBIO1  
1/26/21 – 2EIDX remains 2EIDX  
1/27/21 – 2EIDX becomes 2BBIO1

**DATE:** 1/26/21

On January 19, 2021, Shareholders of Eidos Therapeutics, Inc. (EIDX) voted concerning the proposed merger with BridgeBio Pharma, Inc. (BBIO). The merger was approved and subsequently consummated before the open on January 26, 2021.

**The Merger: Aggregate Terms**

The maximum aggregate amount of cash to be paid to EIDX shareholders in the merger will be \$175 million.

**The Merger: Individual Share Elections**

Within the terms of the Merger, individual EIDX Shareholders may:

- Elect to receive 1.85 BridgeBio Pharma, Inc. (BBIO) Common Shares. (“Stock Consideration”). Cash will be paid in lieu of fractional shares. OR,
- Elect to receive \$73.26 in cash (“Cash Consideration”). Cash Consideration is subject to proration.
- Register no preference by not making an election. **Shares which are not subject to an effective election will then be deemed non-election shares and will receive the Stock Consideration.**

**CONTRACT ADJUSTMENT**

**DATE:** January 26, 2021

**OPTION SYMBOLS:** 1/26/21 – EIDX remains EIDX (with adjusted deliverable described below)  
1/27/21 – EIDX changes to BBIO1  
1/26/21 – 2EIDX remains 2EIDX (with adjusted deliverable described below)  
1/27/21 – 2EIDX changes to 2BBIO1

**STRIKE DIVISOR:** 1

CONTRACT MULTIPLIER: 1

NEW MULTIPLIER: 100 (e.g., for premium or strike price extensions, 1.00 equals \$100)

NEW DELIVERABLE  
PER CONTRACT: The deliverable for adjusted EIDX options will be BASED ON THE MERGER CONSIDERATION WHICH ACCRUES TO NON-ELECTING EIDX SHAREHOLDERS (stated in terms of a current 100-Share deliverable).

185 BridgeBio Pharma, Inc. (BBIO) Common Shares (100 x the Non-Electing Consideration)

CUSIP: BBIO: 10806X102

### **PRICING**

The underlying price for BBIO1/2BBIO1 will be determined as follows:

$$\text{BBIO1} = 1.85 (\text{BBIO})$$

### **DISCLAIMER**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).